<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526396</url>
  </required_header>
  <id_info>
    <org_study_id>STAD-1</org_study_id>
    <secondary_id>2006-003995-36</secondary_id>
    <nct_id>NCT00526396</nct_id>
  </id_info>
  <brief_title>STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study</brief_title>
  <acronym>STAD-1</acronym>
  <official_title>Multicenter Randomized Phase III Study Comparing Fixed Doses Versus Toxicity Adjusted Dosing of Cisplatin and Etoposide for Patients With Small Cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the activity of fixed doses of cisplatin and
      etoposide with toxicity adjusted dosing of the same drugs in the first-line treatment of
      small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard treatment for advanced small cell lung cancer (SCLC) is combination chemotherapy
      of cisplatin or carboplatin with etoposide. Standard fixed doses of this combination have
      been based on calculating a patient's body surface area. This method of dose calculation has
      been shown to be poorly correlated with the activity of many chemotherapy drugs, and some
      patients do not obtain adequate levels of the drug in their circulation. Recent reports
      suggest that patients who have a very high tolerability to chemotherapy (without significant
      toxicity), are at risk for having less effectiveness of the therapy. This study will compare
      fixed doses of standard chemotherapy with a new strategy of the same chemotherapy with doses
      that will be adjusted according to the toxicity observed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response</measure>
    <time_frame>after 3 and 6 cycles of chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>during and after each treatment cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard fixed doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>toxicity adjusted dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>80 mg/m2 on day 1 for 6 cycles</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>100 mg/m2 on days 1,2,3 for 6 cycles</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologic or histologic diagnosis of small cell lung cancer

          -  Extensive disease according to VALG classification

          -  One or more target lesions.

          -  Performance status (ECOG) 0 or 1

          -  Age &lt;70 years.

          -  Patients with asymptomatic cerebral metastases are eligible

          -  Patients who have completed treatment with radiation therapy at least 4 weeks prior to
             enrollment are eligible

          -  Written informed consent

        Exclusion Criteria:

          -  Previous chemotherapy

          -  Previous or concomitant malignant neoplasm (excluding adequately treated baso or
             spinocellular skin carcinoma or carcinoma in situ of the cervix)

          -  Neutrophil &lt; 2000/mm3, platelets &lt; 100,000/mm3, haemoglobin &lt; 10 g/dl

          -  Creatinine &gt; 1.5 x the upper normal limits

          -  GOT and/or GPT &gt; 2.5 and/or Bilirubin &gt; 1.5 times the upper normal limits in absence
             of hepatic metastases

          -  GOT and/or GPT &gt; 5 and/or Bilirubin &gt; 3 times the upper normal limits in presence of
             hepatic metastases

          -  Any concomitant pathology that would, in the investigator's opinion, contraindicate
             the use of the drugs in this study

          -  Hypersensitivity to darbepoetin alpha, to r-HuEPO or their components

          -  Uncontrolled hypertension.

          -  Inability to provide informed consent.

          -  Inability to comply with follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesare Gridelli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>S.G. Moscati Hopital, Avellino, Italy, Division of Medical Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Di Maio, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Giannettasio Hospital, Department of Oncology and Hematology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute Naples, Italy; Director Clinical Trials Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second University of Naples, Italy; Chair of Medical Statistics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Sanitaria S. Giuseppe Moscati</name>
      <address>
        <city>Monteforte Irpino</city>
        <state>AV</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Rummo</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena S.p.A., Dipartimento Oncologico</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale E. Morelli</name>
      <address>
        <city>Sondalo</city>
        <state>SO</state>
        <zip>23039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Lazzaro</name>
      <address>
        <city>Alba</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Domini</name>
      <address>
        <city>Catanzara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale L. Sacco Polo Universitario</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cotugno</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2007</study_first_submitted>
  <study_first_submitted_qc>September 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>toxicity adjusted dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

